Carbidopa/levodopa (WD-1603) vs Rytary (IPX066)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

Carbidopa/levodopa (WD-1603)

Developed by Hong Kong WD Pharmaceutical Co., Limited

Phase 2 in Parkinson's Diseasesmall molecule
Partial signal

NCT05036473 · Phase 2 · completed

This randomized, double-blind, placebo-controlled Phase 2 trial in early Parkinson's disease enrolled only 40 patients across three dose groups and placebo. All three doses of WD-1603 produced a statistically significant improvement in combined motor and daily-living function scores versus placebo at 27 days, with the largest effect at the highest dose (p=0.0003), but the very small sample size means these results need confirmation in a larger trial.

Reported efficacy

To compare the changes from the baseline mean value before the study to the mean value on the 27th day of the study between each dose group and the placebo group. (27 days- from the baseline to the 27th day): Day 27 MDS-UPDRS II+III total score, LS mean change from baseline vs placebo: low dose -6.7 (p=0.0388); medium dose -8.5 (p=0.0125); high dose -13.6 (p=0.0003) (met)

Result source: NCT05036473

Rytary (IPX066)

Marketed by Amneal Pharmaceuticals

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT00974974 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled phase 3 trial with 393 randomized participants. The primary clinical endpoint—percentage of waking hours spent in the Parkinsonian “off” state—favored IPX066 over immediate-release carbidopa-levodopa and was statistically significant (p<0.0001).

Reported efficacy

Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): IPX066 23.82 percentage (Standard Deviation 14.91) vs IR CD-LD (Active Comparator) 29.79 percentage (Standard Deviation 15.81) (met)

Result source: NCT00974974

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointCarbidopa/​levodopa (WD-1603)Rytary (IPX066)
OFF time, change—Not reported—Not reported
ON time without troublesome dyskinesia, change—Not reported—Not reported
UPDRS Part III, change—Not reported21.6 vs 25.5vs IR CD-LDwk 0 · n 27NCT00869791
MDS-UPDRS Part II, change—Not reported—Not reported

OFF time, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Rytary (IPX066)
—Not reported

ON time without troublesome dyskinesia, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Rytary (IPX066)
—Not reported

UPDRS Part III, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Rytary (IPX066)
21.6 vs 25.5vs IR CD-LDwk 0 · n 27NCT00869791

MDS-UPDRS Part II, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Rytary (IPX066)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Carbidopa/levodopa (WD-1603): 0 of 4 rows · Rytary (IPX066): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCarbidopa/​levodopa (WD-1603)Rytary (IPX066)
Dropout rate—
—a
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
24.5%390 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
20.2%245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
17.2%145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
—Part 1: Conversion
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 2: Open-Label Extension 1
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 3: Open-Label Extension 2
NCT01411137 · Phase 3 · registry result, not featured evidence
—
NCT01130493 · Phase 3 · registry result, not featured evidence
8.1%
NCT01096186 · Phase 3 · registry result, not featured evidence
—
NCT00869791 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs—
—a
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
15.3%390 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
14.4%245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
5.7%145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
—Part 1: Conversion
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 2: Open-Label Extension 1
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 3: Open-Label Extension 2
NCT01411137 · Phase 3 · registry result, not featured evidence
—
NCT01130493 · Phase 3 · registry result, not featured evidence
2.6%
NCT01096186 · Phase 3 · registry result, not featured evidence
—
NCT00869791 · Phase 2 · registry result, not featured evidence
Serious AEs—
5.5%a
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
2%390 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
4.8%245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
4.6%145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
2.3%Part 1: Conversion
NCT01411137 · Phase 3 · registry result, not featured evidence
15.6%Part 2: Open-Label Extension 1
NCT01411137 · Phase 3 · registry result, not featured evidence
25%Part 3: Open-Label Extension 2
NCT01411137 · Phase 3 · registry result, not featured evidence
1.1%
NCT01130493 · Phase 3 · registry result, not featured evidence
7%
NCT01096186 · Phase 3 · registry result, not featured evidence
0%
NCT00869791 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs—
a
insomnia 3.5%
fall 3%
nausea 3%
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
390 mg LD
nausea 20.4% (placebo 8.7%)
headache 17.3% (placebo 10.9%)
dizziness 12.2% (placebo 5.4%)
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
245 mg LD
dizziness 19.2% (placebo 5.4%)
nausea 19.2% (placebo 8.7%)
headache 12.5% (placebo 10.9%)
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
145 mg LD
nausea 13.8% (placebo 8.7%)
dizziness 9.2% (placebo 5.4%)
headache 6.9% (placebo 10.9%)
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
nausea 11.6%
dyskinesia 7%
fall 7%
NCT01411137 · Phase 3 · registry result, not featured evidence
upper respiratory infection 15.6%
anxiety 6.3%
fall 6.3%
NCT01411137 · Phase 3 · registry result, not featured evidence
fall 16.7%
orthostatic hypotension 16.7%
anxiety 8.3%
NCT01411137 · Phase 3 · registry result, not featured evidence
dyskinesia 4.5%
confusional state 3.4%
insomnia 3.4%
NCT01130493 · Phase 3 · registry result, not featured evidence
insomnia 5.8%
dyskinesia 5.5%
fall 5.3%
NCT01096186 · Phase 3 · registry result, not featured evidence
anxiety 3.7%
fatigue 3.7%
feeling of warth in abdomen 3.7%
NCT00869791 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Carbidopa/levodopa (WD-1603)

MDS-UPDRS II III -6.7 score @ 3.857142857142857wk
absolute change · score
No placebo or comparator arm
NCT05036473 · Phase 2 · sponsor-reported, not registry data
show 2 more results
-8.5 score @ 3.857142857142857wk
NCT05036473 · Phase 2 · sponsor-reported, not registry data
-13.6 score @ 3.857142857142857wk
NCT05036473 · Phase 2 · sponsor-reported, not registry data

Rytary (IPX066)

Off" Time 23.82% (n=201) vs 29.79% (n=192) IR CD-LD @ 22wk
absolute value · percentage points
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
Off" Time 3.87 vs 4.88 IR CD-LD hours @ 22wk
absolute value · hours
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more results
3.82 vs 5.22 CLE hours @ 2wk
NCT01130493 · Phase 3 · registry result, not featured evidence
3.83 vs 5.83 IR CD-LD hours @ 1wk
NCT00869791 · Phase 2 · registry result, not featured evidence
On" Time Without Troublesome Dyskinesia 11.84 vs 10.91 IR CD-LD hours @ 22wk
absolute value · hours
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 1 more result
11.36 vs 9.98 CLE hours @ 2wk
NCT01130493 · Phase 3 · registry result, not featured evidence
UPDRS II III Sum -14.9 vs -0.6 placebo score @ 30wk390 mg LD
absolute change · score
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more results
-12.9 vs -0.6 placebo score @ 30wk245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
-11.7 vs -0.6 placebo score @ 30wk145mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
PDQ-39 -6 vs 0.6 placebo score @ 30wk390 mg LD
absolute change · score
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more results
-3.8 vs 0.6 placebo score @ 30wk245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
-4.4 vs 0.6 placebo score @ 30wk145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
PGIC 5.2 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT01411137 · Phase 3 · registry result, not featured evidence
show 2 more results
5.4 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
5.3 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
CGI-C 5.5 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT01411137 · Phase 3 · registry result, not featured evidence
show 2 more results
5.7 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
5.6 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
PDQ-8 9.6 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT01411137 · Phase 3 · registry result, not featured evidence
show 3 more results
8.1 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
8.5 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
9 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
Awake OFF Time 23.98% (n=83) vs 32.48% (n=83) CLE @ 2wk
absolute value · percentage points
NCT01130493 · Phase 3 · registry result, not featured evidence
UPDRS Parts II+III 29.3 vs 31.7 CLE score @ 2wk
absolute change · score
NCT01130493 · Phase 3 · registry result, not featured evidence
UPDRS Parts II+III 26.4 score @ 39wk
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01096186 · Phase 3 · registry result, not featured evidence
UPDRS Total 30.5 score @ 39wk
absolute value · score
Extension (open-label)
No placebo or comparator arm
NCT01096186 · Phase 3 · registry result, not featured evidence

+ 4 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carbidopa/levodopa (WD-1603)'s landscape · Rytary (IPX066)'s landscape